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Background
Efavirenz (EFV) and lopinavir/ritonavir (LPV/r) are both
recommended as preferred backbone agents for combina-
tion antiretroviral therapy (cART) in treatment-naïve
patients. Meta-analyses have suggested there is a differ-
ence in the magnitude of CD4 cell count response.
Methods
Within the virtual cohort of the VA clinical case registry
(CCR), we used generalized linear models, accounting for
multiple measurements within patients, to compare CD4
cell counts over a 48-month period following treatment
initiation of either EFV- or LPV/r-containing cART (regard-
less of virologic response).
Summary of results
Between Sept. 1, 2000 and Dec. 31, 2006, 4,298 and
11,618 veterans started LPV/r- and EFV-containing cART,
respectively. Only patients on continuous EFV or LPV/r
therapy with no interruptions >60 days per pharmacy
refill database were analyzed. There was no statistically
significant difference in adherence or time on therapy
between regimens. Baseline mean CD4 counts were 271
and 319, respectively (p < 0.001). Mean CD4 counts
changes are presented in Table 1.
Differences in CD4 changes were most pronounced for
patients with low baseline CD4 count (<50 cells/μL):
ΔCD4 was 303 vs. 206 cells at month 36; p = 0.0344.
Conclusion
Despite significantly lower baseline CD4 count, LPV/r-
based regimens were associated with significantly greater
CD4 gains at 6, 24, and 36 months compared with EFV-
based regimens.
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Table 1: 
Mean values/μL Months on cART 6 12 24 36 48
LPV/r n = 1098 802 472 283 121
ΔCD4 61 81 125 138 171
EFV n = 3089 2409 1644 1136 781
ΔCD4 50 71 94 104 136
Difference in ΔCD4: LPV/r – EFV 11 10 31 34 35
p value for ΔCD4† 0.0294 0.1554 0.0028 0.0229 0.5188
†Scheffé Test for multiple comparisons.
